Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinus banksiana pollen extract is a biological allergenic extract derived from the pollen of the jack pine tree (*Pinus banksiana*). It is primarily utilized as a diagnostic tool in clinical allergy testing, such as skin prick or intradermal tests, to identify individuals with hypersensitivity to jack pine pollen. The extract works by cross-linking allergen-specific IgE antibodies bound to mast cells and basophils in the skin, triggering the release of inflammatory mediators like histamine, which results in a visible wheal-and-flare reaction. Approved by the FDA in 1974 under BLA 102223, it is also used in allergen immunotherapy (desensitization) to reduce allergic symptoms over time in sensitized patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pinus banksiana pollen extract.